TIDMDEMG
RNS Number : 6892U
Deltex Medical Group PLC
30 March 2023
The information contained within this announcement was deemed by
Deltex Medical to constitute inside information as stipulated under
the UK Market Abuse Regulation
30 March 2023
Deltex Medical Group plc
("Deltex Medical" or the "Group")
Results for the year ended 31 December 2022
Deltex Medical Group plc (AIM: DEMG), the global leader in
oesophageal Doppler monitoring, today announces its results for the
year ended 31 December 2022.
HIGHLIGHTS
Financial
-- Revenues increased by 10% to GBP2.5 million (2021: GBP2.3
million)
-- Strong performance by International division with a 30%
increase in revenues to GBP1.2 million (2021: GBP0.9 million)
-- Increase in average selling prices drove gross margin up to
74% (2021: 70%)
-- Overheads held at GBP2.9 million (2021: GBP2.7 million)
-- Adjusted EBITDA of GBP(0.6) million (2021: GBP(0.5)
million)
-- Loss for the year GBP(1.1) million (2021: GBP(1.0)
million)
-- Gross expenditure on research and product development: GBP0.8
million (2021: GBP0.7 million)
-- Cash at hand of GBP0.5 million (2021: GBP0.4 million)
-- Standby loan facility repayment date extension to 30 June
2024
Business / commercial activities
-- Sales of the current monitor were strong across all three
divisions in 2022: UK: +83%; USA: +126% and International: +253%;
historically, monitor sales have given rise to increased probe
sales
-- Further growth from the International division expected
-- As previously reported, the Group has been participating in a
national tender for haemodynamic monitoring with one of its Latin
American distributors. Hospitals have now started to place orders
with this distributor in a contract process that is expected to
continue for some 2 months, by when further information on the
orders to be placed on Deltex Medical should be known
-- New targeted commercial approach in the USA to drive
increases in revenues on a more cost effective and region-by-region
basis
-- The external Electromagnetic Compatibility testing required
to obtain regulatory approval to launch the new monitor onto the UK
and European markets has been successfully concluded which allows
the final testing and associated internal documentation to be
completed.
-- Work is continuing on the new, novel non-invasive TrueVue ODM
technology with a substantial addressable market
Related party transaction
On 22 December 2022 Deltex Medical announced an extension to a
standby loan facility (the "Loan") provided by Imperialise Limited,
a company controlled by Nigel Keen, Chairman of Deltex Medical, of
which he is a director. Mr. Keen has now agreed to extend the
repayment date for the Loan from 31 December 2023 to 30 June 2024
(the "Transaction"). All other terms relating to the Loan remain
unchanged. The Transaction constitutes a related party transaction
with Nigel Keen under Rule 13 of the AIM Rules for Companies.
Accordingly, the directors independent of the Transaction, being
Andy Mears, Natalie Wettler, Julian Cazalet, Tim Irish, Christopher
Jones and Mark Wippell, having consulted with Deltex Medical's
nominated adviser, Allenby Capital, consider that the terms of the
Transaction are fair and reasonable insofar as the Group's
shareholders are concerned.
Commenting on the results, Nigel Keen, Chairman of Deltex
Medical, said:
"We are encouraged by double digit growth in revenues during the
year."
"The performance of the International division has been notably
strong over the last two years - and we are expecting continuing
progress this year."
"The 'heavy lifting' has been done in terms of new product
development - and we are expecting the level of investment in
R&D to reduce going forwards."
"The launch of the new, next generation monitor will be
extremely helpful for sales across all our territories - both via
direct sales and our overseas distributors."
For further information, please contact:
Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman investorinfo@Deltexmedical.com
Andy Mears, Chief Executive
Natalie Wettler, Group Finance Director
Nominated Adviser & Broker
Allenby Capital Limited 020 3328 5656
Jeremy Porter / Vivek Bhardwaj (Corporate info@allenbycapital.com
Finance)
Tony Quirke / Stefano Aquilino (Sales & Corporate
Broking)
Notes for Editors
Deltex Medical's technology
Deltex Medical's TrueVue System uses proprietary haemodynamic
monitoring technology to assist clinicians to improve outcomes for
patients as well as increase throughput and capacity for
hospitals.
Deltex Medical has invested over the long term to build a unique
body of peer-reviewed, published evidence from a substantial number
of trials carried out around the world. These studies demonstrate
statistically significant improvements in clinical outcomes
providing benefits both to patients and to the hospital systems by
increasing patient throughput and expanding hospital capacity.
The Group's flagship, world-leading, ultrasound-based
oesophageal Doppler monitoring ("ODM") is supported by 24
randomised control trials conducted on anaesthetised patients. As a
result, the primary application for ODM is focussed on guiding
therapy for patients undergoing elective surgery. The Group will
shortly launch a new, next generation monitor which will make the
use of the ODM technology more intuitive and provide augmented data
on the status of each patient.
Deltex Medical's engineers and scientists carried out successful
research in conjunction with the UK's National Physical Laboratory
("NPL"), which has enabled the Group's 'gold standard' ODM
technology to be extended and developed so that it can be used
completely non-invasively. This will significantly expand the
application of Deltex Medical's technology to non-sedated patients.
This new technological enhancement, which will be released on the
new next generation monitor, will substantially increase the
addressable market for the Group's haemodynamic monitoring
technologies and is complementary to the long-established ODM
evidence base.
Deltex Medical's new non-invasive technology has potential
applications for use in a number of healthcare settings,
including:
-- Accident & Emergency for the rapid triage of patients,
including the detection and diagnosis of sepsis;
-- in general wards to help facilitate a real-time, data-driven
treatment regime for patients whose condition might deteriorate
rapidly; and
-- in critical care units to allow regular monitoring of
patients post-surgery who are no longer sedated or intubated.
One of the key opportunities for the Group is positioning this
new, non-invasive technology for use throughout the hospital.
Deltex Medical's haemodynamic monitoring technologies provide
clinicians with beat-to-beat real-time information on a patient's
circulating blood volume and heart function. This information is
critical to enable clinicians to optimise both fluid and drug
delivery to patients.
Deltex Medical's business model is to drive the recurring
revenues associated with the sale of single-use disposable ODM
probes which are used in the TrueVue System and to complement these
revenues with a new incremental revenue stream to be derived from
the Group's new non-invasive technology.
Both the existing single-use ODM probe and the new, non-invasive
device will connect to the same, next generation monitor which is
due for launch in 2023. Monitors are sold or, due to hospitals'
often protracted procurement times for capital items, loaned in
order to encourage faster adoption of the Group's technology.
Deltex Medical's customers
The principal users of Deltex Medical's products are currently
anaesthetists working in a hospital's operating theatre and
intensivists working in ICUs. This customer profile will change as
the Group's new non-invasive technology is adopted by the market.
In the UK the Group sells directly to the NHS. In the USA the Group
sells directly to a range of hospital systems. The Group also sells
through distributors in more than 40 countries in the European
Union, Asia and the Americas.
Deltex Medical's objective
To see the adoption of Deltex Medical's next generation TrueVue
System, comprising both minimally invasive and non-invasive
technologies, as the standard of care in haemodynamic monitoring
for all patients from new-born to adult, awake or anaesthetised,
across all hospital settings globally.
For further information please go to www.deltexmedical.com
CHAIRMAN'S STATEMENT
Financial results
Group revenues for the year ended 31 December 2022 increased by
10% to GBP2.5 million (2021: GBP2.3 million), assisted by another
strong performance from the Group's International division.
Last year we announced that the International division had
achieved a 40% increase in revenues to GBP0.9 million. This year we
can announce that the division posted a further 30% increase in
revenues to GBP1.2 million. We believe that there is further
profitable revenue growth to be generated by this division.
Probe revenues declined slightly to GBP1.8 million (2021: GBP1.9
million).
Group monitor sales increased by a robust 166% to GBP0.5 million
(2021: GBP0.2 million). This is a good result taking into account
that these monitor sales related to the current version of the
monitor.
Gross margin increased again in 2022 to 74% (2020: 70%)
reflecting enhanced discipline in relation to our pricing policies
and a proactive campaign to obtain inflationary increases in price
points. The gross margin also benefited from the relative weakness
of sterling against the US dollar.
Overheads increased 4% to GBP2.9 million (2021: GBP2.7
million).
Adjusted EBITDA (comprising earnings before interest, tax,
depreciation and amortization, share-based payments and
non-executive directors' fees) was a loss of GBP(0.6) million
(2021: GBP(0.5) million). Adjusted EBITDA is reconciled to
operating loss in note 3 in the notes at the back of this
document.
Gross cash expenditure on research and product development by
the Group (excluding the effect of grants or capitalisation of
product development) amounted to GBP0.8 million (2021: GBP0.7
million). The net amount, having taken into account grants, was
GBP0.7 million (2021: GBP0.6 million). Our plans anticipate
expenditure on research and product development to decline during
2023.
Operating loss for the year was GBP(0.9) million (2021: GBP(0.8)
million).
Loss for the year was GBP(1.1) million (2021: GBP(1.0)
million).
Cash at hand at 31 December was GBP0.5 million (2021: GBP0.4
million).
Business activities
Deltex Medical sells directly, via its own sales teams, into UK
and US hospitals. We continue to see significant constraints
imposed on our sales teams in terms of being able to access key
decision makers in UK and US hospitals' operating theatres ("ORs")
and intensive care units ("ICUs"). Notwithstanding these specific
sales-related challenges, we did see a substantial increase in
sales of monitors in both territories. Sales of monitors into UK
hospitals increased by 77% and into US hospitals by 122%. We
believe that this substantial increase in monitor sales is all the
more impressive given that the market is aware that Deltex Medical
will shortly launch a new, next generation monitor.
Although probe sales declined slightly in both our direct
markets, the fact that customers increased significantly their
purchases of monitors is, we believe, extremely encouraging as
historically probe revenues have tended to increase in accounts
where monitors have recently been purchased.
Deltex Medical's International division continues to impress
with a 30% revenue growth recorded in the year. In the last two
years revenues have nearly doubled from GBP0.7 million to GBP1.2
million. We have worked carefully on a rolling programme of cost
reduction initiatives to ensure that the Group's monitors and
probes both enjoy significant gross margins. As a result, we are
able to sell on a profitable basis to hospitals around the world
via our extensive network of overseas distributors. We believe that
there is further growth to come from our International division.
The Group has been participating in a national tender for
haemodynamic monitoring with one of its Latin American
distributors. Hospitals have now started to place orders with this
distributor in a contract process that is expected to continue for
some two months, by when further information on the orders to be
placed on Deltex Medical should be known.
Significant progress has been made on the development of Deltex
Medical's new monitor. The external Electromagnetic Compatibility
testing required to obtain regulatory approval to launch the new
monitor onto the UK and European markets has been successfully
concluded which allows the final testing and associated internal
documentation to be completed. This is expected to take
approximately two months.
The launch of this new, next generation monitor enables us to
progress to the next stage of our strategic product development
programme, including the development of the new non-invasive
TrueVue ODM technology which has a substantial addressable
market.
Employees
On behalf of the Board, I would like to thank Deltex Medical's
high quality and dedicated employees for their hard work during the
year. The adverse after-effects of the Covid pandemic continued to
be felt in a number of ways during 2022 and we very much appreciate
the key contributions from our UK and overseas teams.
Current trading and prospects
The significant increase in monitor sales in all three divisions
in 2022 augurs well for increases in probe revenues in the
future.
We believe that there continue to be significant opportunities
for growth from the International division, and we are particularly
focussed on maximising the commercial benefits associated with a
national tender in Latin America.
We are seeing strong interest in our new monitor, particularly
from the UK, and we believe that its launch will also help drive
revenues in 2023.
The fact that the new monitor is substantially complete is
extremely helpful in terms of reducing the quantum of cash
expenditure on new product development going forwards. Further, we
will be able to free up our technical teams to carry out broader
customer support activities as well as more targeted, and less
capital intensive, product development.
2023 has started well.
Nigel Keen
Chairman
29 March 2023
BUSINESS REVIEW
Overview
Deltex Medical is the world leader in high accuracy oesophageal
Doppler monitoring ("ODM"), via its TrueVue platform, which allows
real-time monitoring of a patient's haemodynamic status.
A substantial number of peer-reviewed, randomised controlled
trials have demonstrated that an ODM-driven haemodynamic protocol
can result in statistically significant reductions in
post-operative complications such as acute kidney injuries,
resulting in lower costs for hospitals due to shorter patient
length-of-stay. This is not only good for patients but also
increases throughput and capacity for hospitals, which should be a
key factor for reducing the backlog in elective surgery,
particularly in the UK.
Deltex Medical's technology was originally developed in a London
ICU to assist with the treatment of acutely unwell critical care
patients. Over time demand for the Group's high fidelity
oesophageal Doppler-based haemodynamic monitoring technology has
migrated from the ICU to the OR, and particularly for complex
elective surgical procedures.
Before the Covid pandemic, approximately 80% of the Group's
revenues were associated with elective surgical procedures in ORs.
The near-complete cessation of elective surgery during the pandemic
was highly disruptive to Deltex Medical's commercial activities,
particularly in the UK and the USA, where the Group sells its
technology directly. Although elective surgery has re-started
around the world as the pandemic subsides, Deltex Medical's sales
teams are still experiencing more restricted levels of access to
the OR and ICU than they enjoyed pre-pandemic.
Our key challenge for 2023 is to maximise the commercial
benefits for the Group of the launch of the new monitor. We are
also hoping to land a significant Latin American contract for both
monitors and probes. We will also continue to educate, in
conjunction with our overseas distributors, decision-makers in
hospitals about the potential capacity / throughput-related and
financial benefits associated with using the Deltex Medical TrueVue
ODM technology during elective surgery.
Three principal divisions: UK, USA and International
Deltex Medical's commercial activities are structured across
three divisions: the UK; the USA and International.
The Group has not yet managed to drive commercial activity up to
pre-pandemic levels in the UK and US divisions for a number of
reasons. Many hospitals have imposed significant restrictions on
salespersons or clinical educators accessing ORs or ICUs. Once
hospitals stop using Deltex Medical's ODM technology, it can take
some time to re-instigate the use of ODM via updated standard
operating procedures. We have also been restricting, particularly
in the USA, expenditure on sales and marketing activities as we
diverted resources into completing the development of our new
monitor. We know from experience that where our sales personnel are
unable to obtain meaningful face-to-face access to anaesthetists,
or other appropriate OR staff, then probe usage typically declines
over time.
One way in which we have been seeking to mitigate the impact of
greater restrictions for our sales teams in meeting hospital-based
decision-makers in person is by increasing the use of online
materials, including training via the launch of the online Deltex
Medical Academy.
Notwithstanding some of the challenges that the Group has faced
in terms of accessing customers, we have been encouraged by a
significant year-on-year increase in monitor revenues into our
three divisions: UK (+ 77%); USA (+122%); and International (+
221%). It is notable that these increases all relate to the current
version of the monitor. These monitor sales should result in
increased probe revenues which will be helpful in terms of driving
up high margin recurring revenues in the future.
In the UK we have seen strong interest via pre-launch
educational presentations for our new monitor from a number of NHS
hospitals. We believe that there will be significant demand for the
new monitor once it is formally fully launched onto the UK
market.
There remains a substantial backlog in elective surgery in the
UK. This backlog represents both an opportunity and a challenge for
the Group. For example, there are powerful arguments, supported by
the published evidence base, that the use of Deltex Medical's
TrueVue technology increases patient throughput in the hospital and
improves patient outcomes, thereby helping reduce the size (and
associated cost) of the elective surgery backlog. Conversely, we
have seen evidence in some NHS hospitals that the senior management
teams are under pressure to reduce the backlog and, notwithstanding
the peer-reviewed published evidence base, are reluctant to promote
the adoption of new technology at this time.
In 2022, mindful of the need to conserve our cash resources, we
decided to adopt a more focussed and targeted sales and marketing
strategy in the USA. For example, we have been supporting the trial
and evaluation of the TrueVue ODM technology in a Top 5 US hospital
system on the East coast. Thus far the feedback from this
prestigious hospital has been most encouraging. As and when this
leading US hospital decides to roll out the use of TrueVue on a
protocolised basis, we believe that this will be extremely helpful
for Deltex Medical to generate new customer accounts in the region.
Adopting such a targeted regional approach is a significantly more
cost-effective way of expanding the Group's coverage of the
important US market. We intend to replicate this targeted approach
with other leading US hospital systems in different regions, and
build back up our US coverage on a region-by-region basis.
In 2022 the International division had another good year with
overall revenue growth of 30% to GBP1.2 million (2021: GBP0.9
million). A substantial proportion of this growth came from Latin
America. We continue to support our network of international
distributors closely. Many of these distributors have long-standing
and close relationships with ORs in hospitals, and enjoy privileged
access to key decision makers.
There has been consolidation among suppliers of haemodynamic
monitoring equipment over the last five years. This has resulted in
consolidation of sales teams. As a result, on a number of occasions
Deltex Medical has benefited from less competition in certain
territories.
Product development and innovation
During 2022, our research and development team were focussed on
completing the development of our new, next generation TrueVue
monitor. This task was made more challenging by pandemic-related
disruption to electronic supply-chains. There is some evidence that
the disruption to these supply chains is beginning to abate.
In order to obtain the necessary regulatory approvals to launch
the new monitor onto the UK and European markets, there is a
requirement to complete Electromagnetic Compatibility (EMC)
testing. EMC testing is carried out through an external test house
and these tests have recently been successfully completed.
Now EMC testing has been completed the device can be passed
through acoustic testing and the internal documentation required to
support the regulatory submissions can be finalised. This
self-certification process is expected to be completed shortly
following which the new monitor will be available for sale in the
UK and European markets.
Once the new monitor has been successfully launched in the UK
and Europe, we intend to complete the necessary FDA filings to
obtain US regulatory approval so that the new, next generation
monitor should be launched onto the US market next year. We are
expecting to sell the new monitor into new accounts as well as
existing customers that wish to upgrade their ODM technology.
Following the launch of the new monitor , we will be refocussing
our research and development team to work on a complementary,
non-invasive haemodynamic monitoring technology which leverages the
extensive evidence base supporting the use of our existing ODM
technology. This new technology will allow instantaneous
non-invasive haemodynamic monitoring, via the new monitor, anywhere
in the hospital. This new, novel technology should substantially
broaden the potential applications, and hence addressable market
size, for the Group's Doppler-based ultrasound technology.
We are continuing to work with the UK's National Physical
Laboratory to explore how the use of cutting-edge science will
enable us to improve the performance and data generation from
Deltex Medical's core ultrasound technology. We anticipate
advancing this research project significantly in 2023.
Regulatory
Deltex Medical designs and manufactures Class II medical devices
which it sells around the world. As a result, its business
activities can be significantly affected by changes to regulations.
The post-Brexit regulatory regime in the UK, as well as for UK
companies selling into Europe, is still evolving and we keep actual
or prospective changes in applicable regulations under close
scrutiny.
In Europe the transition from the Medical Device Directive to
the European Medical Device Regulation ("MDR") has been deferred
until 2028. Although this reduces some regulatory-associated
complexity in the short term, there is still considerable
uncertainty as to what steps will be required, by when, for a Class
II medical device manufacturer to comply with MDR in the
future.
Conclusion
Completion of the new monitor will greatly enhance Deltex
Medical's technological offering to the market as well as opening
up the possibility to use this device as a platform for further
product line extensions. We are particularly interested in the
commercial potential associated with the easier-to-use non-invasive
haemodynamic monitoring technology which we are also
developing.
So far market feedback and demand for the new monitor has been
encouraging, both from prospective and existing customers, and we
see its launch as a critical building block in driving up probe
revenues across all three divisions.
We have concluded that the Covid era restrictions imposed on
salespersons to stop them from enjoying relatively open access to
ICUs and ORs will continue in the future. We have taken a number of
mitigation steps to enable us to commercialise successfully our
technology with this 'new normal' in mind.
Andy Mears
Chief Executive
29 March 2023
Consolidated statement of comprehensive income
For the year ended 31 December 2022
2022 2021
GBP'000 GBP'000
------------------------------------------------------- -------------------- -----------
Revenue 2,482 2,259
Cost of sales (643) (684)
------------------------------------------------------- -------------------- -----------
Gross profit 1,839 1,575
Administrative expenses (1,560) (1,585)
Sales and distribution expenses (1,027) (957)
Research and Development, Quality and Regulatory (231) (207)
Impairment loss on trade receivables (39) -
Total costs (2,857) (2,749)
------------------------------------------------------- -------------------- -----------
Other operating income - 312
------------------------------------------------------- -------------------- -----------
Other gain 71 57
------------------------------------------------------- -------------------- -----------
Operating loss (947) (805)
------------------------------------------------------- -------------------- -----------
Finance costs (199) (173)
------------------------------------------------------- -------------------- -----------
Loss before taxation (1,146) (978)
Tax credit on loss 1 12
------------------------------------------------------- -------------------- -----------
Loss for the year (1,145) (966)
------------------------------------------------------- -------------------- -----------
Other comprehensive expense
Items that may be reclassified to profit or
loss:
Net translation differences on overseas subsidiaries 35 (2)
------------------------------------------------------- -------------------- -----------
Other comprehensive expense for the year,
net of tax 35 (2)
------------------------------------------------------- -------------------- -----------
Total comprehensive loss for the year (1,110) (968)
------------------------------------------------------- -------------------- -----------
Total comprehensive loss for the year attributable
to:
Owners of the Parent (1,114) (969)
Non-controlling interests 4 1
------------------------------------------------------- -------------------- -----------
(1,110) (968)
------------------------------------------------------- -------------------- -----------
Loss per share - basic and diluted (0.17p) (0.17p)
------------------------------------------------------- -------------------- -----------
Consolidated balance sheet
As at 31 December 2022
Company Number 03902895
2022 2021
GBP'000 GBP'000
------------------------------------- -------- ------------------
Assets
Non-current assets
Property, plant and equipment 269 264
Intangible assets 3,769 3,135
Financial assets at amortised cost 164 157
-------------------------------------- -------- ------------------
Total non-current assets
Current assets 4,202 3,556
Inventories 821 796
Trade receivables 456 455
Financial assets at amortised cost 15 15
Other current assets 140 91
Current income tax recoverable 72 69
Cash and cash equivalents 471 413
-------------------------------------- -------- ------------------
Total current assets 1,975 1,839
-------------------------------------- -------- ------------------
Total assets 6,177 5,395
-------------------------------------- -------- ------------------
Liabilities
Current liabilities
Borrowings (935) (702)
Trade and other payables (1,704) (1,478)
-------------------------------------- -------- ------------------
Total current liabilities (2,639) (2,180)
-------------------------------------- -------- ------------------
Non-current liabilities
Borrowings (1,069) (1,028)
Trade and other payables (177) (228)
Provisions (64) (57)
-------------------------------------- -------- ------------------
Total non-current liabilities (1,310) (1,313)
-------------------------------------- -------- ------------------
Total liabilities (3,949) (3,493)
-------------------------------------- -------- ------------------
Net assets 2,228 1,902
-------------------------------------- -------- ------------------
Equity
Share capital 6,990 5,849
Share premium 33,672 33,502
Capital redemption reserve 17,476 17,476
Other reserve 527 573
Translation reserve 168 133
Convertible loan note reserve 82 82
Accumulated losses (56,566) (55,588)
-------------------------------------- -------- ------------------
Equity attributable to owners of
the Parent 2,349 2,027
Non-controlling interests (121) (125)
-------------------------------------- -------- ------------------
Total equity 2,228 1,902
-------------------------------------- -------- ------------------
Consolidated statement of changes in equity for the year ended
31 December 2022
Capital Convertible
Share Share redemption Other loan note Translation Accumulated Non-controlling Total
capital premium reserve reserve reserve reserve losses Total interest equity
----------------
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
---------------- ------------ -------------- ------------------- ------------- -------------- ------------ ------------ ------- --------------- -------
Balance at 1
January
2022 5,849 33,502 17,476 573 82 133 (55,588) 2,027 (125) 1,902
Comprehensive
income
Loss for the
period - - - - - - (1,149) (1,149) 4 (1,145)
Other
comprehensive
income for the
period - - - - - 35 - 35 - 35
---------------- ------------ -------------- ------------------- ------------- -------------- ------------ ------------ ------- --------------- -------
Total
comprehensive
income for
year - - - - - 35 (1,149) (1,114) 4 (1,110)
Transactions
with owners of
the Group
Shares issued
during the
year 1,141 285 - - - - - 1,426 - 1,426
Issue expenses - (115) - - - - - (115) - (115)
Equity-settled
share- based
payment - - - 125 - - - 125 - 125
Transfers - - - (171) - - 171 - - -
---------------- ------------ -------------- ------------------- ------------- -------------- ------------ ------------ ------- --------------- -------
Balance at
31 December
2022 6,990 33,672 17,476 527 82 168 (56,566) 2,349 (121) 2,228
---------------- ------------ -------------- ------------------- ------------- -------------- ------------ ------------ ------- --------------- -------
Consolidated statement of changes in equity for the year ended
31 December 2021
Capital Convertible Non-
Share Share redemption Other loan note Translation Accumulated Total controlling
capital premium reserve reserve reserve reserve losses interest
Total
equity
----------------
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
GBP'000
---------------- ------------ -------------- ------------------- ------------- -------------- ------------ ------------ ------- ------------------
Balance at 1
January
2021 5,773 33,444 17,476 505 82 135 (54,648) 2,767 (126) 2,641
Comprehensive
income
Loss for the
period - - - - - - (967) (967) 1 (966)
Other
comprehensive
income for the
period - - - - - (2) - (2) - (2)
---------------- ------------ -------------- ------------------- ------------- -------------- ------------ ------------ ------- ------------------
Total
comprehensive
income for
year - - - - - (2) (967) (969) 1 (968)
Transactions
with owners of
the Group
Shares issued
during the
year 76 58 - - - - - 134 - 134
Equity-settled
share- based
payment - - - 95 - - - 95 - 95
Transfers - - - (27) - - 27 - - -
---------------- ------------ -------------- ------------------- ------------- -------------- ------------ ------------ ------- ------------------
Balance at
31 December
2021 5,849 33,502 17,476 573 82 133 (55,588) 2,027 (125) 1,902
---------------- ------------ -------------- ------------------- ------------- -------------- ------------ ------------ ------- ------------------
Consolidated statement of cash flows
for the year ended 31 December 2022
2022 2021
GBP'000 GBP'000
----------------------------------------------------- -------------------- ---------
Cash flows from operating activities
Loss before taxation (1,146) (978)
Adjustments for:
Finance costs 199 173
Depreciation of property, plant and equipment 88 74
Amortisation of intangible assets 40 40
Share-based payment expense 125 95
Other gain (71) ( 57)
Effect of exchange rate fluctuations 35 (2)
----------------------------------------------------- -------------------- ---------
(730) (655)
(Increase)/Decrease in inventories (48) 89
(Increase)/Decrease in trade and other receivables (57) 148
Increase in trade and other payables 306 191
Increase in provisions 7 6
----------------------------------------------------- -------------------- ---------
Net cash used in operations (522) (221)
Interest paid (153) (131)
RDEC taxes received 69 61
----------------------------------------------------- -------------------- ---------
Net cash used in operating activities (606) (291)
Cash flows from investing activities
Purchase of property, plant and equipment (70) (23)
Capitalised development expenditure (net
of grants) (674) (621)
----------------------------------------------------- -------------------- ---------
Net cash used in investing activities (744) (644)
Cash flows from / (used in) financing activities
Issue of ordinary share capital 1,340 -
Expenses in connection with share issue (115) -
Net movement in invoice discount facility (17) 43
Standby loan facility repayment (500) -
Standby loan facility drawdown 750 500
Principal lease payments (45) (41)
----------------------------------------------------- -------------------- ---------
Net cash generated from financing activities 1,413 502
----------------------------------------------------- -------------------- ---------
Net increase/(decrease) in cash and cash
equivalents 63 (433)
Cash and cash equivalents at beginning of
the period 413 853
Exchange loss on cash and cash equivalents (5) (7)
----------------------------------------------------- -------------------- ---------
Cash and cash equivalents at end of the
period 471 413
----------------------------------------------------- -------------------- ---------
1. Nature of the financial information
This Results Summary containing condensed financial information
for the year ended 31 December 2022 should be read in conjunction
with the Deltex Medical Group Plc's Annual Report & Accounts
2022 which were prepared in accordance with UK-adopted
International Accounting Standards . The consolidated financial
statements have been prepared under the historical cost convention
and on a going concern basis.
Financial information contained in this document does not
constitute statutory accounts within the meaning of section 434 of
the Companies Act 2006 ('the Act'). The statutory accounts for the
year ended 31 December 2021 have been filed with the Registrar of
Companies and those for the year ended 31 December 2022 will be
filed with the Registrar of Companies following the Annual General
Meeting. The report of the independent auditor on those statutory
accounts was unqualified, did not draw attention to any matters by
way of emphasis and did not contain a statement under section
498(2) or (3) of the Act. The report for year ended 31 December
2021 of the independent auditor on those statutory accounts was
unqualified and did not contain a statement under section 498(2) or
(3) of the Act.
2. Accounting policies
The Group's principal accounting policies can be found in the
Group's Annual Report & Accounts 2022.
Going concern
The Group meets its day-to-day working capital requirements
through a combination of operational cash flows, an invoice
discounting facility and, if required, the raising of additional
finance.
In December 2022, the Group extended the standby loan facility
with Imperialise Limited by GBP250,000 to GBP750,000 in order to
help fund the costs to complete the new monitor. The Group intends
to repay the GBP250,000 as soon as possible and specifically when
positive operating cashflow is generated by way of sales of the new
monitor. All other terms of the standby loan facility, which was
issued in September 2021, remain unchanged. Furthermore, on 29
March 2023, the maturity date of the standby loan facility was
extended from 31 December 2023 to 30 June 2024.
In February 2023, the maturity date of the convertible loan
notes was extended from 26 February 2024 to 30 June 2026. All other
terms of the convertible loan notes, which were issued in February
2016, remain unchanged.
The Directors have reviewed detailed budgets and forecasts until
30 June 2024. In making their forecasts, the Directors have
carefully considered the possible continued after effects of
post-Covid restrictions and associated disruption on the Group's
business. This review indicates that the Group is expected to
continue trading as a going concern based on projected net cash
flows derived from sales of the Group.
The Directors consider that they have reasonable grounds to
believe that the Group will have adequate resources to continue in
operational existence for the foreseeable future and it is
therefore appropriate to prepare the financial statements on the
going concern basis.
3. Revenue and EBITDA
For the year ended 31 December 2022
Direct Indirect markets
Probes markets Other Probes Monitors Other Total
Monitors
------------------
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
------------------ ---------- --------------- ----------------- -------------------- ----------- ----------
UK 461 106 75 - - - 642
USA 463 122 51 - - - 636
France - - - 464 1 15 8 487
Latin America - - - 90 212 2 304
South Korea - - - 132 - - 132
Hong Kong - - - 13 32 3 48
Austria - - - 44 - 2 46
Cayman Islands - - - 24 18 1 43
Other countries 19 30 - 90 2 3 144
------------------ ---------- --------------- ----------------- -------------------- ----------- ----------
943 258 126 857 279 19 2,482
------------------ ---------- --------------- ----------------- -------------------- ----------- ----------
1. Total revenue for this segment relates to a single external customer
For the year ended 31 December 2021
Direct markets Indirect markets
Probes Monitors Other Probes Monitors Other Total
------------------
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
------------------ ---------- ----------------- ----------------- -------------------- ----------- ----------
UK 524 60 86 - - - 670
USA 561 55 47 - - - 663
France - - - 489 1 29 8 526
Scandinavia - - - 105 - 2 107
South Korea - - - 134 - 2 136
Portugal - - - 35 - - 35
Other countries 10 - - 53 58 1 122
------------------ ---------- ----------------- ----------------- -------------------- ----------- ----------
1,095 115 133 816 87 13 2,259
------------------ ---------- ----------------- ----------------- -------------------- ----------- ----------
1. Total revenue for this segment relates to a single external customer
The Group's revenue disaggregated between the sale of goods and
the provision of services is set out below. All revenues from the
sale of goods are recognised at a point in time; maintenance income
is recognised at the point the service is carried out.
2022 2021
GBP'000 GBP'000
-------------------- -------- --------------
Sale of goods 2,430 2,192
Maintenance income 52 67
-------------------- -------- --------------
2,482 2,259
-------------------- -------- --------------
The reconciliation of Adjusted EBITDA used by the Group's Chief
Operating Decision Maker (CODM) to the result reported in the
Group's consolidated SOCI is set out below:
2022 2021
GBP'000 GBP'000
------------------------------------------------ ---------- ---------------
Adjusted EBITDA (607) (504)
Non-cash items:
Depreciation of property, plant and equipment (88) (74)
Amortisation of development costs (40) (40)
Impairment loss on trade receivables (39) -
Non-executive directors' fees and employer's
NIC (136) (138)
Share-based payment expenses (125) (95)
Change in accumulated absence cost liability 17 (11)
Cash item:
Other tax income 71 57
------------------------------------------------ ---------- ---------------
(340) (301)
------------------------------------------------ ---------- ---------------
Operating loss (947) (805)
Finance costs (199) (173)
------------------------------------------------ ---------- ---------------
Loss before tax (1,146) (978)
Tax credit on loss 1 12
------------------------------------------------ ---------- ---------------
Loss for the year (1,145) (966)
------------------------------------------------ ---------- ---------------
The following table provides information about trade receivables
and contract liabilities from contracts with customers. There were
no contract assets at either 31 December 2022 or 31 December
2021.
31 December 31 December
----------------------------------------
2022 2021
----------------------------------------
GBP'000 GBP'000
---------------------------------------- ----------- -----------
Trade receivables which are in 'Trade
and other receivables' 456 455
Contract liabilities (39) (57)
---------------------------------------- ----------- -----------
The following aggregated amounts of transaction prices relate to
the performance obligations from existing contracts that are
unsatisfied or partially unsatisfied as at 31 December 2022:
2023 2024 2025 2026 Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
---------------------- ------------------- ----------------- ------------------ ------------------ ----------
Revenue expected to
be recognised 25 2 2 10 39
---------------------- ------------------- ----------------- ------------------ ------------------ ----------
Revenue recognised in 2022 which was included in contract
liabilities at 31 December 2021 amounted to GBP30,000. Revenue
recognised in 2021 included in contract liabilities at 31 December
2020 amounted to GBP54,000.
4. Dividends
The directors cannot recommend payment of a dividend (2021:
nil).
5. Basic and diluted loss per share
The loss per share calculation is based on the loss of
GBP1,149,000 and the weighted average number of shares in issue of
685,490,974. For 2021, the loss per share calculation is based on
the loss of GBP967,000 and the weighted average number of shares in
issue of 580,712,339. While the Group is loss-making, the diluted
loss per share and the loss per share are the same.
6. Subsequent events
On 27 February 2023, the maturity date of the convertible loan
notes was extended from 26 February 2024 to 30 June 2026. All other
terms of the convertible loan notes, which were issued in February
2016, remain unchanged. The Group have considered the financial
impact of this modification to the loan's maturity date and
determined that it is not substantial resulting in an estimated
gain of GBP89,000 which will be recognised in the Consolidated
Statement of Comprehensive Income for the year ended 31 December
2023.
On 29 March 2023, the maturity date of the standby loan facility
was extended from 31 December 2023 to 30 June 2024. All other terms
of the standby loan facility, which was initially issued in
September 2021, remain unchanged.
Distribution of Annual Report and Accounts
The Group will shortly be posting a copy of the Annual Report
and Accounts for the year ended 31 December 2022 to shareholders,
together with a Notice of Annual General Meeting to be held at
11.00 am on 17 May 2023 at the offices of DAC Beachcroft LLP, 25
Walbrook, London, EC4N 8AF.
A copy of the Annual Report and Accounts and the Notice of
Annual General Meeting will also shortly be available from the
Group's website at www.deltexmedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FR UKVBROKUOUAR
(END) Dow Jones Newswires
March 30, 2023 02:00 ET (06:00 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024